Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19199788 | 0.78 | MEN1 (0.36) | CA12CA14CA1CA7CA2 | |
| SCHEMBL7176207 | 0.71 | DGAT1 (0.34) | CA12CA14CA1CA7CA2 | |
| SCHEMBL18510032 | 0.71 | DGAT1 (0.34) | CA12CA14CA1CA7CA2 | |
| SCHEMBL16766811 | 0.69 | HDAC6 (0.41) | CA12CA1CA2NR1D1 | |
| SCHEMBL2803665 | 0.68 | CA12 (0.33) | CA12CA1CA2 | |
| SCHEMBL13981283 | 0.68 | CYP2D6 (0.38) | CA12CA14CA1CA7CA2 | |
| SCHEMBL27420033 | 0.68 | NR1D1 (0.38) | CA12CA14CA1CA7CA2 | |
| SCHEMBL22059570 | 0.68 | CA12 (0.33) | CA12CA14CA1CA7CA2 | |
| SCHEMBL13676332 | 0.67 | CYP2D6 (0.33) | CA12CA14CA1CA7CA2 | |
| SCHEMBL17308796 | 0.67 | CYP2D6 (0.33) | CA12CA14CA1CA7CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11078170-B2 | Cyclic sulfamide compounds and methods of using same | ASSEMBLY BIOSCIENCES, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-20200157070-A1 | CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME | ASSEMBLY BIOSCIENCES INC (US) | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11078170-B2 | Cyclic sulfamide compounds and methods of using same | HCCS, HAVCR2, SLC10A1 | CA12 283/4885CA14 335/4885CA1 1186/4885 |
| US-20200157070-A1 | CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME | HCCS, HAVCR2, SLC10A1 | CA12 283/4885CA14 335/4885CA1 1186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.